中国组织工程研究 ›› 2024, Vol. 28 ›› Issue (3): 458-463.doi: 10.12307/2023.879
• 生物材料综述 biomaterial review • 上一篇 下一篇
陈俊炎1,孟庆奇2,李斯明1,2
收稿日期:
2022-12-20
接受日期:
2023-02-04
出版日期:
2024-01-28
发布日期:
2023-07-10
通讯作者:
李斯明,博士,主任医师,博士生导师,贵州医科大学,贵州省贵阳市 550025;暨南大学附属广州市红十字会医院,广东省广州市 510220
作者简介:
陈俊炎,男,1996年生,浙江省温州市人,汉族,医师,贵州医科大学在读硕士,主要从事关节损伤及修复方面相关研究。
Chen Junyan1, Meng Qingqi2, Li Siming1, 2
Received:
2022-12-20
Accepted:
2023-02-04
Online:
2024-01-28
Published:
2023-07-10
Contact:
Li Siming, MD, Chief physician, Doctoral supervisor, Guizhou Medical University, Guiyang 550025, Guizhou Province, China; Guangzhou Red Cross Hospital, Jinan University, Guangzhou 510220, Guangdong Province, China
About author:
Chen Junyan, Master candidate, Physician, Guizhou Medical University, Guiyang 550025, Guizhou Province, China
摘要:
文题释义:
软骨靶向:指和软骨成分包括软骨细胞及细胞外基质等结合的能力,可以特异性地递送药物或载体到软骨内部形成药库,达到缓释和精准治疗效果。
背景:关节腔注射给药已经在骨关节炎治疗中占有重要地位,新型的药物递送系统的开发给予了更多选择。软骨靶向功能是针对治疗骨关节炎时药物附着或留置在软骨层中形成药库,达到缓释和精准药物递送。
目的:综述关节腔注射治疗骨关节炎中各种软骨靶向生物材料和其特点。结果与结论:针对软骨靶向生物材料的研究,主要分为两个方向。一是利用静电作用的相互结合,如携带正电荷的生物材料与软骨中的负电多糖结合,这类方案可操作性强,便于修饰,但受限于静电作用本身的缺点,在晚期骨关节炎中表现不佳;二是针对软骨内各成分的特异性结合,这种结合强而可靠,相关生物材料在晚期骨关节炎中表现优异,是未来软骨靶向治疗的重要方向。
https://orcid.org/0000-0002-5535-5437(陈俊炎)
中国组织工程研究杂志出版内容重点:生物材料;骨生物材料;口腔生物材料;纳米材料;缓释材料;材料相容性;组织工程
中图分类号:
陈俊炎, 孟庆奇, 李斯明. 关节腔注射治疗骨关节炎药物载体系统中的软骨靶向功能[J]. 中国组织工程研究, 2024, 28(3): 458-463.
Chen Junyan, Meng Qingqi, Li Siming. Cartilage targeting function in the drug delivery system by intra-articular injection for the treatment of osteoarthritis[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(3): 458-463.
[1] BAJPAYEE AG, GRODZINSKY AJ. Cartilage-targeting drug delivery: can electrostatic interactions help?. Nat Rev Rheumatol. 2017;13(3):183-193. [2] MENG H, QUAN Q, YUAN X, et al. Diffusion of neutral solutes within human osteoarthritic cartilage: Effect of loading patterns. J Orthop Translat. 2019;22:58-66. [3] LE MERDY M, MULLIN J, LUKACOVA V. Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study. J Pharmacokinet Pharmacodyn. 2021;48(6):909-922. [4] GONZÁLEZ OSUNA A, ROJAS LF, LAMAS C, et al. Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement. Clin Pharmacokinet. 2022;61(1):83-95. [5] ZHANG M, HU W, CAI C, et al. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment. Mater Today Bio. 2022;14:100223. [6] LIMA AC, FERREIRA H, REIS RL, et al. Biodegradable polymers: an update on drug delivery in bone and cartilage diseases. Expert Opin Drug Deliv. 2019;16(8):795-813. [7] ASPBERG A. The different roles of aggrecan interaction domains. J Histochem Cytochem. 2012;60(12):987-996. [8] VEDADGHAVAMI A, ZHANG C, BAJPAYEE AG. Overcoming negatively charged tissue barriers: Drug delivery using cationic peptides and proteins. Nano Today. 2020;34: 100898. [9] BROWN S, KUMAR S, SHARMA B. Intra-articular targeting of nanomaterials for the treatment of osteoarthritis. Acta Biomater. 2019;93:239-257. [10] BAJPAYEE AG, WONG CR, BAWENDI MG, et al. Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis. Biomaterials. 2014;35(1):538-549. [11] BAJPAYEE AG, SCHEU M, GRODZINSKY AJ, et al. Electrostatic interactions enable rapid penetration, enhanced uptake and retention of intra-articular injected avidin in rat knee joints. J Orthop Res. 2014;32(8):1044-1051. [12] BAJPAYEE AG, DE LA VEGA RE, SCHEU M, et al. Sustained intra-cartilage delivery of low dose dexamethasone using a cationic carrier for treatment of post traumatic osteoarthritis. Eur Cell Mater. 2017;34:341-364. [13] BAJPAYEE AG, QUADIR MA, HAMMOND PT, et al. Charge based intra-cartilage delivery of single dose dexamethasone using Avidin nano-carriers suppresses cytokine-induced catabolism long term. Osteoarthritis Cartilage. 2016;24(1):71-81. [14] HE T, ZHANG C, VEDADGHAVAMI A, et al. Multi-arm Avidin nano-construct for intra-cartilage delivery of small molecule drugs. J Control Release. 2020;318:109-123. [15] HE T, SHAW I, VEDADGHAVAMI A, et al. Single-Dose Intra-Cartilage Delivery of Kartogenin Using a Cationic Multi-Arm Avidin Nanocarrier Suppresses Cytokine-Induced Osteoarthritis-Related Catabolism. Cartilage. 2022;13(2):19476035221093072. [16] GEIGER BC, WANG S, PADERA RF JR, et al. Cartilage-penetrating nanocarriers improve delivery and efficacy of growth factor treatment of osteoarthritis. Sci Transl Med. 2018;10(469):eaat8800. [17] HU Q, DING B, YAN X, et al. Polyethylene glycol modified PAMAM dendrimer delivery of kartogenin to induce chondrogenic differentiation of mesenchymal stem cells. Nanomedicine. 2017;13(7):2189-2198. [18] SCHNEIDER T, WELKER P, HAAG R, et al. Effects of dendritic polyglycerol sulfate on articular chondrocytes. Inflamm Res. 2015;64(11):917-928. [19] PERNI S, PROKOPOVICH P. Optimisation and feature selection of poly-beta-amino-ester as a drug delivery system for cartilage. J Mater Chem B. 2020;8(23):5096-5108. [20] VEDADGHAVAMI A, HE T, ZHANG C, et al. Charge-based drug delivery to cartilage: Hydrophobic and not electrostatic interactions are the dominant cause of competitive binding of cationic carriers in synovial fluid. Acta Biomater. 2022;151:278-289. [21] VEDADGHAVAMI A, WAGNER EK, MEHTA S, et al. Cartilage penetrating cationic peptide carriers for applications in drug delivery to avascular negatively charged tissues. Acta Biomater. 2019;93:258-269. [22] VEDADGHAVAMI A, HAKIM B, HE T, et al. Cationic peptide carriers enable long-term delivery of insulin-like growth factor-1 to suppress osteoarthritis-induced matrix degradation. Arthritis Res Ther. 2022;24(1):172 . [23] LIN J, CHEN L, YANG J, et al. Injectable Double Positively Charged Hydrogel Microspheres for Targeting-Penetration-Phagocytosis. Small. 2022;18(40):e2202156. [24] KRISHNAN Y, REES HA, ROSSITTO CP, et al. Green fluorescent proteins engineered for cartilage-targeted drug delivery: Insights for transport into highly charged avascular tissues. Biomaterials. 2018;183:218-233. [25] KRISHNAN Y, YANG YJ, BARNES SK, et al. Predicting transport of intra-articularly injected growth factor fusion proteins into human knee joint cartilage. Acta Biomater. 2022;153: 243-259. [26] HWANG HS, PARK IY, KIM HA, et al. PEP-1-GRX-1 Modulates Matrix Metalloproteinase-13 and Nitric Oxide Expression of Human Articular Chondrocytes. Cell Physiol Biochem. 2017;41(1):252-264. [27] YAN H, DUAN X, PAN H, et al. Suppression of NF-κB activity via nanoparticle-based siRNA delivery alters early cartilage responses to injury. Proc Natl Acad Sci U S A. 2016; 113(41):E6199-E6208. [28] YAN H, DUAN X, PAN H, et al. Development of a peptide-siRNA nanocomplex targeting NF-κB for efficient cartilage delivery. Sci Rep. 2019;9(1):442. [29] WANG S, WEI X, SUN X, et al. A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system. Int J Nanomedicine. 2018;13:617-631. [30] HE K, HUANG X, SHAN R, et al. Intra-articular Injection of Lornoxicam and MicroRNA-140 Co-loaded Cationic Liposomes Enhanced the Therapeutic Treatment of Experimental Osteoarthritis. AAPS PharmSciTech. 2021;23(1):9. [31] LEI Y, WANG Y, SHEN J, et al. Injectable hydrogel microspheres with self-renewable hydration layers alleviate osteoarthritis. Sci Adv. 2022;8(5):eabl6449. [32] EBADA HM, NASRA MM, NASSRA RA, et al. Cationic nanocarrier of rhein based on hydrophobic ion pairing approach as intra-articular targeted regenerative therapy for osteoarthritis. Colloids Surf B Biointerfaces. 2022;211:112285. [33] BROWN S, PISTINER J, ADJEI IM, et al. Nanoparticle Properties for Delivery to Cartilage: The Implications of Disease State, Synovial Fluid, and Off-Target Uptake. Mol Pharm. 2019;16(2):469-479. [34] CHEN L, TIWARI SR, ZHANG Y, et al. Facile Synthesis of Hollow MnO2 Nanoparticles for Reactive Oxygen Species Scavenging in Osteoarthritis. ACS Biomater Sci Eng. 2021; 7(4):1686-1692. [35] KUMAR S, ADJEI IM, BROWN SB, et al. Manganese dioxide nanoparticles protect cartilage from inflammation-induced oxidative stress. Biomaterials. 2019;224:119467. [36] WEI Y, YAN L, LUO L, et al. Phospholipase A2 inhibitor-loaded micellar nanoparticles attenuate inflammation and mitigate osteoarthritis progression. Sci Adv. 2021;7(15): eabe6374. [37] BOTTINI M, BHATTACHARYA K, FADEEL B, et al. Nanodrugs to target articular cartilage: An emerging platform for osteoarthritis therapy. Nanomedicine. 2016; 12(2):255-268. [38] BROWN SB, WANG L, JUNGELS RR, et al. Effects of cartilage-targeting moieties on nanoparticle biodistribution in healthy and osteoarthritic joints. Acta Biomater. 2020; 101:469-483. [39] ROTHENFLUH DA, BERMUDEZ H, O’NEIL CP, et al. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mater. 2008;7(3):248-254. [40] FORMICA FA, BARRETO G, ZENOBI-WONG M. Cartilage-targeting dexamethasone prodrugs increase the efficacy of dexamethasone. J Control Release. 2019;295:118-129. [41] JIANG T, KAN HM, RAJPURA K, et al. Development of Targeted Nanoscale Drug Delivery System for Osteoarthritic Cartilage Tissue. J Nanosci Nanotechnol. 2018;18(4):2310-2317. [42] AI X, DUAN Y, ZHANG Q, et al. Cartilage-targeting ultrasmall lipid-polymer hybrid nanoparticles for the prevention of cartilage degradation. Bioeng Transl Med. 2020;6(1): e10187. [43] 南方医科大学珠江医院. 软骨靶向纳米颗粒及其制备方法和应用: CN202210265953.5[P]. 2022-07-29. [44] HU HY, LIM NH, DING-PFENNIGDORFF D, et al. DOTAM derivatives as active cartilage-targeting drug carriers for the treatment of osteoarthritis. Bioconjug Chem. 2015;26(3): 383-388. [45] LAN Q, LU R, CHEN H, et al. MMP-13 enzyme and pH responsive theranostic nanoplatform for osteoarthritis. J Nanobiotechnology. 2020;18(1):117. [46] HE Y, REN E, LU Z, et al. Rational engineering of ferritin nanocages for targeted therapy of osteoarthritis. Nanomedicine. 2020;28:102210. [47] LU Y, CHEN J, LI L, et al. Hierarchical functional nanoparticles boost osteoarthritis therapy by utilizing joint-resident mesenchymal stem cells. J Nanobiotechnology. 2022;20(1):89. [48] HULME JT, D’SOUZA WN, MCBRIDE HJ, et al. Novel protein therapeutic joint retention strategy based on collagen-binding Avimers. J Orthop Res. 2018;36(4):1238-1247. [49] COOK SANGAR ML, GIRARD EJ, HOPPING G, et al. A potent peptide-steroid conjugate accumulates in cartilage and reverses arthritis without evidence of systemic corticosteroid exposure. Sci Transl Med. 2020;12(533):eaay1041. [50] CHO H, PINKHASSIK E, DAVID V, et al. Detection of early cartilage damage using targeted nanosomes in a post-traumatic osteoarthritis mouse model. Nanomedicine. 2015;11(4):939-946. [51] CHO H, KIM BJ, PARK SH, et al. Noninvasive visualization of early osteoarthritic cartilage using targeted nanosomes in a destabilization of the medial meniscus mouse model. Int J Nanomedicine. 2018;13:1215-1224. [52] BEDINGFIELD SK, COLAZO JM, YU F, et al. Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage. Nat Biomed Eng. 2021;5(9):1069-1083. [53] CHEUNG CS, LUI JC, BARON J. Identification of chondrocyte-binding peptides by phage display. J Orthop Res. 2013;31(7):1053-1058. [54] ARDEN NK, PERRY TA, BANNURU RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17(1):59-66. [55] JAIN A, MISHRA SK, VUDDANDA PR, et al. Targeting of diacerein loaded lipid nanoparticles to intra-articular cartilage using chondroitin sulfate as homing carrier for treatment of osteoarthritis in rats. Nanomedicine. 2014;10(5):1031-1040. [56] MILLER RE, GRODZINSKY AJ, CUMMINGS K, et al. Intraarticular injection of heparin-binding insulin-like growth factor 1 sustains delivery of insulin-like growth factor 1 to cartilage through binding to chondroitin sulfate. Arthritis Rheum. 2010;62(12):3686-3694. [57] BISHNOI M, JAIN A, HURKAT P, et al. Aceclofenac-loaded chondroitin sulfate conjugated SLNs for effective management of osteoarthritis. J Drug Target. 2014;22(9):805-812. [58] EBADA HMK, NASRA MMA, NASSRA RA, et al. Chondroitin sulfate-functionalized lipid nanoreservoirs: a novel cartilage-targeting approach for intra-articular delivery of cassic acid for osteoarthritis treatment. Drug Deliv. 2022;29(1):652-663. [59] PI Y, ZHANG X, SHI J, et al. Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display. Biomaterials. 2011; 32(26):6324-6332. [60] LIANG Y, XU X, XU L, et al. Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment. Theranostics. 2022;12(11):4866-4878. [61] HU Q, CHEN Q, YAN X, et al. Chondrocyte affinity peptide modified PAMAM conjugate as a nanoplatform for targeting and retention in cartilage. Nanomedicine (Lond). 2018; 13(7):749-767. [62] LIN JB, POH S, PANITCH A. Controlled release of anti-inflammatory peptides from reducible thermosensitive nanoparticles suppresses cartilage inflammation. Nanomedicine. 2016;12(7):2095-2100. [63] OUYANG Z, TAN T, LIU C, et al. Targeted delivery of hesperetin to cartilage attenuates osteoarthritis by bimodal imaging with Gd2(CO3)3@PDA nanoparticles via TLR-2/NF-κB/Akt signaling. Biomaterials. 2019;205:50-63. [64] D’ATRI D, ZERRILLO L, GARCIA J, et al. Nanoghosts: Mesenchymal Stem cells derived nanoparticles as a unique approach for cartilage regeneration. J Control Release. 2021; 337:472-481. [65] KIM YG, CHOI J, KIM K. Mesenchymal Stem Cell-Derived Exosomes for Effective Cartilage Tissue Repair and Treatment of Osteoarthritis. Biotechnol J. 2020;15(12):e2000082. [66] COLOMBINI A, RAGNI E, MORTATI L, et al. Adipose-Derived Mesenchymal Stromal Cells Treated with Interleukin 1 Beta Produced Chondro-Protective Vesicles Able to Fast Penetrate in Cartilage. Cells. 2021;10(5):1180. [67] SACCHETTI C, LIU-BRYAN R, MAGRINI A, et al. Polyethylene-glycol-modified single-walled carbon nanotubes for intra-articular delivery to chondrocytes. ACS Nano. 2014; 8(12):12280-12291. |
[1] | 毕玉杰, 马笃军, 彭力平, 周紫琼, 赵 静, 朱厚均, 钟秋辉, 杨玉鑫. 中医药联合医用水凝胶治疗疾病的策略及意义[J]. 中国组织工程研究, 2024, 28(3): 419-425. |
[2] | 高雪钰, 张文涛, 孙天泽, 张 警, 李忠海. 金属离子在骨组织工程中的应用[J]. 中国组织工程研究, 2024, 28(3): 439-444. |
[3] | 杨 杰, 胡浩磊, 李 硕, 岳 玮, 徐 弢, 李 谊. 3D打印生物墨水在组织修复与再生医学中的应用[J]. 中国组织工程研究, 2024, 28(3): 445-451. |
[4] | 孔祥宇, 王 兴, 裴志伟, 常家乐, 李斯琴, 郝 廷, 何万雄, 张葆鑫, 贾燕飞. 生物支架材料及打印技术修复骨缺损[J]. 中国组织工程研究, 2024, 28(3): 479-485. |
[5] | 刘宝方, 徐 斌, 陈 雷. 葛根汤治疗骨关节炎的网络药理学分析及动物实验验证[J]. 中国组织工程研究, 2024, 28(2): 193-199. |
[6] | 孟志成, 乔卫平, 赵 阳, 刘洪飞, 李凯杰, 马 博. 免疫细胞及相关细胞因子在骨关节炎发病及治疗中的作用[J]. 中国组织工程研究, 2024, 28(2): 280-287. |
[7] | 何宛俞, 程乐平. 干细胞移植修复脊髓损伤的策略与进展[J]. 中国组织工程研究, 2023, 27(在线): 1-7. |
[8] | 申飞燕, 姚吉祥, 苏珊珊, 赵忠民, 唐巍东. 敲低环状RNA WD重复含蛋白1抑制膝骨关节炎软骨细胞增殖并诱导凋亡[J]. 中国组织工程研究, 2023, 27(在线): 1-6. |
[9] | 李晓敏, 田向东 , 谭冶彤 , 朱光宇 , 王荣田 , 王 剑 , 薛志鹏, 马 晟, 胡元一, 黄 叶, 丁天送. 骨质疏松性内侧室膝骨关节炎胫骨高位截骨后下肢力线及膝关节功能的变化[J]. 中国组织工程研究, 2023, 27(9): 1325-1329. |
[10] | 黄林科, 韦林华, 蒋 捷, 刘 倩, 陈蔚蔚. 雌激素与跑台运动干预卵巢切除模型小鼠骨量和关节软骨的变化[J]. 中国组织工程研究, 2023, 27(8): 1166-1171. |
[11] | 徐 聪, 赵 赫, 孙 岩. 生物材料导管修复面神经损伤与再生[J]. 中国组织工程研究, 2023, 27(7): 1089-1095. |
[12] | 陈世崧, 刘晓红, 徐志云. 人工生物瓣膜的研究现状及展望[J]. 中国组织工程研究, 2023, 27(7): 1096-1102. |
[13] | 许其静, 杨伊春, 雷 微, 杨 莹, 余 江, 夏婷婷, 张 萌, 章 涛, 张 潜. 糖尿病皮肤慢性创面无细胞治疗的进展与问题[J]. 中国组织工程研究, 2023, 27(6): 962-969. |
[14] | 袁长深, 官岩兵, 李 哲, 容伟明, 廖书宁, 陈乐伟, 梅其杰, 段 戡. 骨关节炎坏死性凋亡关键基因的筛选与验证[J]. 中国组织工程研究, 2023, 27(5): 695-700. |
[15] | 谷明西, 王 博, 田丰德, 安 宁, 郝瑞胡, 王常成, 郭 林. 同期和分期双侧全膝关节置换的早期疗效和安全性比较[J]. 中国组织工程研究, 2023, 27(4): 565-571. |
1.3 质量评估及文献筛选 对初次检索文献的标题和摘要进行初步筛选,排除与骨关节炎和软骨不相关的文献,其中纳入万方数据库中文专利1篇,PubMed数据库外文相关文献131篇,详细阅读每篇文章,对其具体研究内容机制进行筛选归类,最后选择67篇文章进行综述,包括中文文献1篇、外文文献66篇,来源于国际机构作者文献51篇,来源于国内机构作者16篇。文献筛选流程图,见图1。
#br#
文题释义:
软骨靶向:指和软骨成分包括软骨细胞及细胞外基质等结合的能力,可以特异性地递送药物或载体到软骨内部形成药库,达到缓释和精准治疗效果。目前对于软骨靶向的研究根据其作用机制不同,处于不同的阶段。作者认为,从现有的软骨靶向研究结果来看,特异性结合的主动靶向对比静电基质有着一定的优势,能更好地完成骨关节炎环境下递送药物的需求,未来软骨靶向研究的方向可以根据软骨的组成成分,开发新型的特异性结合肽,如特异性结合骨髓间充质干细胞等,以满足不同作用靶点的药物的靶向释放需求,为临床关节腔注射治疗骨关节炎提供指导。
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||